robo4 Inhibitors
Robo4 inhibitors as a chemical class involve compounds that inhibit Robo4 signaling indirectly by impacting associated pathways. Given that direct Robo4 inhibitors are scarce or under-researched, the focus has been on the broader signaling mechanisms that are known to interact with or modulate the angiogenic processes that Robo4 is a part of. These chemicals often inhibit kinases like VEGFR, PDGFR, and FGFR or modulate cellular processes like integrin-mediated adhesion, which are key to endothelial cell function and vascular development. Many of these inhibitors are multi-kinase inhibitors, reflecting the complex interplay of signaling pathways that converge on angiogenesis-a central process influenced by Robo4. The specificity of the modulation achieved by these inhibitors can indirectly influence Robo4 signaling by changing the cellular context in which Robo4 operates. For example, by targeting VEGFR, a kinase inhibitor not only reduces VEGF signaling but also has the ability to shift the balance of signaling pathways within the cell, leading to a decrease in the activities that Robo4 promotes.
The class of Robo4 inhibitors underscores the significance of indirect modulation of target proteins through the manipulation of interrelated signaling cascades. The intersectionality of pathways targeted by these inhibitors with Robo4's role in angiogenesis suggests that altering these pathways can impact Robo4 activity. Each inhibitor, through its unique mechanism, contributes to an altered cellular environment, which may either promote or reduce the efficiency of the processes governed by Robo4. Collectively, these chemicals represent a strategy to modulate Robo4 by broadening the scope beyond direct interaction to include the wider signaling landscape that influences Robo4 function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib malate, a receptor tyrosine kinase inhibitor, targets VEGF receptors, which participate in the same angiogenic pathways as Robo4. By impeding VEGF signaling, sunitinib can indirectly reduce Robo4-mediated endothelial cell migration and vessel formation. | ||||||
Met Kinase Inhibitor | 658084-23-2 | sc-204801 | 1 mg | $116.00 | 5 | |
Met Kinase Inhibitor (SU11274) selectively inhibits Met, a receptor tyrosine kinase involved in angiogenesis and vascular repair. Inhibition of Met can attenuate downstream signaling that may intersect with Robo4-mediated pathways, thereby reducing its activity. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
As an integrin antagonist, Cilengitide disrupts cell adhesion and migration. Integrins work closely with Robo4 in endothelial cells; therefore, cilengitide's modulation of integrin activity can indirectly affect Robo4 signaling involved in vascular development. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that targets Src family kinases, which are associated with angiogenic signaling pathways. By inhibiting these kinases, dasatinib can indirectly alter Robo4 signaling. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
This triple angiokinase inhibitor affects VEGF, FGF, and PDGF receptors, potentially modulating pathways that are co-regulated with Robo4, thus altering its signaling in a secondary manner. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib targets VEGF receptors among others and may indirectly diminish Robo4 signaling by modulating angiogenic pathways in which Robo4 is involved. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor with potential to indirectly inhibit Robo4 signaling by targeting Raf-1, B-Raf, and VEGFR kinases that can impact the pathways Robo4 participates in. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases, potentially impacting Robo4 signaling indirectly by modulating the cellular context and signaling environment related to angiogenesis and endothelial cell function. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
As a multi-target inhibitor affecting VEGFR, PDGFR, and FGFR, regorafenib has the potential to impact Robo4 indirectly by modulating the signaling milieu and affecting pathways that are engaged by Robo4 in vascular stability and angiogenesis. | ||||||